Study shows that blood poisoning drug withdrawn by manufacturer may be effective after all

A controversial drug used to treat patients with severe sepsis (a whole-body inflammatory response often bought on by blood poisoning) withdrawn by manufacturer Eli Lilly in October 2011 due to concerns over its efficacy may offer some benefit to patients after all, according to a new systematic review of the evidence published in the Lancet Infectious Diseases.

The drug, called drotrecogin alfa (activated) and marketed by manufacturer Eli Lilly as Xigris, was approved for use in the United States in 2001, and in Europe in 2002, on the basis of the randomised, double-blind, placebo-controlled PROWESS study.

However, concerns were raised over the drug's efficacy and side-effects, and a second clinical study (PROWESS-SHOCK) led to Eli Lilly withdrawing the drug in October 2011, with the US FDA () making a Safety Announcement in which it stated that drotrecogin alfa (activated) treatment should be stopped in patients being treated with the drug, and no new patients should be prescribed the drug.

The Article published today [Monday, July 16] examines real-life usage of the drug over a period of ten years, and concludes that the efficacy of Xigris is, in fact, comparable to that suggested by the original PROWESS trial. Use of the drug was associated with an 18% reduction in the relative risk of death in hospital for with severe sepsis, and the authors found no significant differences between the mortality reductions reported by industry-sponsored and independent controlled studies.

According to the study's authors, Dr Andre Kalil of the University of Nebraska Medical Center, USA, and Dr Steven LaRosa of Beverly Hospital, USA, "Compared with the PROWESS trial, real-life use of drotrecogin alfa (activated) was associated with…a similar and significant reduction in the risk of death…Our effectiveness findings accord with PROWESS but not with the PROWESS-SHOCK trial."

Dr Jean-Louis Vincent of the Free University of Brussels, the author of a linked Comment published alongside the Article, said: "Although these data might not represent the highest levels of evidence, many of us (including me) maintain that we can learn a lot from such real-life studies. The death rate from sepsis is unacceptable and new drugs are needed urgently, so one might ask whether drotrecogin alfa (activated) can be resurrected. However, unfortunately Eli Lilly has given up and the cannot be produced easily."*

More information:
Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Mississippi sues pharmaceutical company

Jul 25, 2006

Mississippi has filed a legal action against Eli Lilly and Co. alleging a plan to defraud the state of millions of dollars in Medicaid reimbursements.

Mississippi sues pharmaceutical company

Jul 25, 2006

Mississippi has filed a legal action against Eli Lilly and Co. alleging a plan to defraud the state of millions of dollars in Medicaid reimbursements.

Risk said associated with Eli Lilly drug

Nov 05, 2007

A new experimental drug from Indianapolis-based Eli Lilly and Co. has been found to have a risk of major bleeding, sometimes even death, a report says.

Recommended for you

Express Scripts turns to AbbVie in huge hepatitis C deal

1 hour ago

The nation's largest pharmacy benefits manager is throwing its weight into a fight over the high cost of treating hepatitis C, saying it will cover a drug from AbbVie while pulling back on those from rival drugmakers.

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.